Non-Renounceable rights Issue Prospectus
Filed with ASX · · 45 pages · English
Summary by 6ix AI
Biotron Limited has filed a prospectus for a non-renounceable rights issue, offering new shares to eligible shareholders at a specified price and ratio. The company aims to raise funds to support its acquisition of Sedarex Limited and ongoing development of its antiviral portfolio. The prospectus outlines the terms of the offer, including the potential for shareholders to apply for additional shares if there is a shortfall. It also emphasizes the speculative nature of the investment and advises shareholders to read the entire document carefully.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Biotron
- Acquisition of Sedarex Limited and $2.5m capital raising
- Trading Halt
- Pause in Trading
- Full Year Statutory Accounts and Appendix 4E
- Rights Issue Closed
Later from Biotron
- Security Class Suspension from Quotation - BITO
- Rights Issue Close
- Security Class Reinstatement to Quotation - BITO
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Issue of the Entitlement Offer Shortfall
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron